Last updated: December 2, 2023
Sponsor: Tanta University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Diabetic Retinopathy
Treatment
Phacoemulsification for cataract
Clinical Study ID
NCT04594603
34082/9/20
Ages 30-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Presence of a nuclear, cortical cataract or complicated cataract due to diabeticmellitus
- Intraocular pressure (IOP) of 21 mm Hg or lower
- Axial length (AL) between 20.0 mm and 25.0 mm.
Exclusion
Exclusion Criteria:
- Eyes with an AL longer than 25.0 mm or shorter than 20.0 mm,
- IOP higher than 21 mm Hg,
- History of ocular trauma or intraocular surgery, or any abnormal intraocularfindings
- Poor OCT-A images because of severe cataracts or unstable fixation
- Any signs of intraoperative or postoperative complications
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Phacoemulsification for cataract
Phase:
Study Start date:
April 13, 2021
Estimated Completion Date:
December 30, 2024
Study Description
Connect with a study center
Tanta University Hospital
Tanta, El-Garbeia 31515
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.